The aim of MAPPs is to enable quicker access for patients whilst providing adequate and evolving evi...
Read moreBased on the current clinical data, the PCSK9 inhibitors are a vital new treatment option for patien...
Read moreThe aim of this study was to assess the launch price of mCRPC treatments across the EU5 (France, Ger...
Read moreIncluded is the P&R challenges faced by the PCSK9 inhibitors as well as how payers are trying to ove...
Read moreIt is the responsibility of CCGs to manage their local drug budgets
Read moreThis article contains official prices at the ex-manufacturer, wholesaler and pharmacy selling price ...
Read moreIn this issue is an overview of the future changes to the UK Cancer Drug Fund as well as approaches ...
Read morePharmaceutical companies are now launching curative treatments, in addition to drugs which only mana...
Read moreNHS England have recently proposed that NICE should take a more direct role in determining which pro...
Read moreThis study determines if EU pricing and reimbursement bodies have revised their pricing and reimburs...
Read more